IL25 and colorectal carcinoma: Indeed, inhibiting IL-25-signalling or ILC2s in an AOM/DSS model of colitis-associated-cancer (CAC) subtype of CRC exacerbated tumors (52–54), while subcutaneous combined implants of sorted human ILC2s and EpCAM+ CRC tumor cells in immunodeficient mice can promote tumor growth, albeit in an immunocompromised setting (19).